Figure 1From: Control of hyperuricemia in subjects with refractory gout, and induction of antibody against poly(ethylene glycol) (PEG), in a phase I trial of subcutaneous PEGylated urate oxidasePlasma uricase activity and plasma uric acid concentration after subcutaneous injection of PEG-uricase. A single 8 mg injection of PEG-modified recombinant mammalian urate oxidase (PEG-uricase) was administered. The horizontal axis indicates days after dosing.Back to article page